Cargando…
Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience
PURPOSE: To present our real-life experience with dabrafenib and trametinib (D-T) treatment in patients with BRAF V600E-mutated ATC in Argentina. PATIENTS Y METHODS: We included five patients from four different hospitals. The median age was 70 years, and 60% were male. The performance status at dia...
Autores principales: | Bueno, Fernanda, Smulever, Anabella, Califano, Inés, Guerra, Jorgelina, Del Grecco, Andrés, Carrera, Juan Manuel, Giglio, Raúl, Rizzo, Manglio, Lingua, Alejo, Voogd, Ana, Negueruela, María del Carmen, Abelleira, Erika, Pitoia, Fabian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838471/ https://www.ncbi.nlm.nih.gov/pubmed/36617605 http://dx.doi.org/10.1007/s12020-022-03295-2 |
Ejemplares similares
-
Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
por: Bueno, Fernanda, et al.
Publicado: (2021) -
Thyroid cancer in the Era of COVID-19
por: Smulever, Anabella, et al.
Publicado: (2020) -
Active surveillance in low risk papillary thyroid carcinoma
por: Pitoia, Fabian, et al.
Publicado: (2020) -
Active surveillance in papillary thyroid carcinoma: not easily accepted but possible in Latin America
por: Smulever, Anabella, et al.
Publicado: (2019) -
Conservative management of low-risk papillary thyroid carcinoma: a review of the active surveillance experience
por: Smulever, Anabella, et al.
Publicado: (2023)